Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

Core Viewpoint - Palvella Therapeutics, Inc. has successfully closed an upsized public offering, raising $230 million to support the development of its therapies for rare skin diseases and vascular malformations [1][3]. Group 1: Offering Details - The public offering consisted of 1,840,000 shares of common stock, priced at $125.00 per share, including the full exercise of the underwriters' option for an additional 240,000 shares [1]. - The offering was managed by several financial institutions, including TD Cowen, Cantor, and Stifel, among others [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to advance the development of Palvella's product candidates, specifically QTORIN rapamycin and QTORIN pitavastatin, as well as for general corporate purposes including research and development expenses [3]. Group 3: Company Overview - Palvella Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for serious, rare skin diseases and vascular malformations, with no FDA-approved treatments currently available [6]. - The company's lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel, targets microcystic lymphatic malformations and other skin conditions, while QTORIN™ pitavastatin is aimed at treating disseminated superficial actinic porokeratosis [6].